In this Medscape commentary, Dr. Scott Kopetz of MD Anderson unpacks the rising role of ctDNA in colorectal cancer. Unlike traditional risk factors, ctDNA offers a real-time snapshot of tumor biology with powerful prognostic value. From guiding adjuvant therapy decisions in stage 2 and 3 disease to detecting recurrence months before imaging, the test is reshaping how oncologists think about surveillance and trial design. With sensitivity still evolving and novel therapies on the horizon, is ctDNA about to become the new backbone of CRC management?
Trending
- Finding freedom as a physician through entrepreneurship (American Medical Association)
- Regulatory burdens continue to mount for physician practices (Fierce Healthcare)
- The unconventional players in the physician acquisition game (Becker’s ASC Review)
- Why Gastroenterology Is One of the Most In-Demand Locums Specialties (Hayes Locums)
- Snailing colorectal cancer drug delivery, once and for all (BioTechniques)
- Goodbye colonoscopy? New stool test detects 90% of colorectal cancers (Science Daily)
- CBT for IBS: A Frontline Treatment, Not Adjunct Therapy (Gastroenterology Advisor)
- Clinical practice update: Electrosurgery guidance refines endoscopy practice (GI & Hepatology News)
